In another study, the team showed that upregulation of HERC3 levels predicted lighter and smaller tumors of patients with CRC, decreased CRC cell growth, and arrested the cell cycle, probably via targeting RPL23A as its major substrate for degradation [71]. Here, HERC3 is linked to colorectal carcinoma.